Reference intervals for glycated albumin during physiological pregnancy of Europid women: Evidences from a prospective observational study.


Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
15 Feb 2023
Historique:
received: 17 12 2022
revised: 02 02 2023
accepted: 02 02 2023
pubmed: 9 2 2023
medline: 15 3 2023
entrez: 8 2 2023
Statut: ppublish

Résumé

Glycated albumin (GA) may assess glycometabolic control over a short period of time respect to HbA Forty-five healthy pregnant Europid women have been enrolled for whom a GDM screening test was scheduled at 24-28 weeks, in 5 different Italian centers. Only those negative to the OGTT were included. The women had 4 successive visits at 6-10 weeks of gestation, at 16-18 weeks, at 24-28 weeks and at the end of pregnancy. ALT, AST, total bilirubin, C-reactive protein, cholinesterase, creatinine, GGT, glycated albumin, iron, total serum proteins, transferrin were measured in duplicate on aliquots of serum samples by a central laboratory. The RI (2.5-97.5 percentiles) for GA were 11.1-14.8 % (I visit), 10.9-15.6 % (II visit), 10.6-14.1 % (III visit) and 10.7-14.3 % (IV visit). The RI of other biomarkers confirmed previously published data. The RI for serum cholinesterase we present are novel, and were 5049-9906 U/L (Iv), 4212-8965 U/L (IIv), 3518-8470 U/L (IIIv) and 3945-8727 U/L (IVv). Trimester-specific RI are important for using GA and serum cholinesterase in pregnancy. However, considering the high inter-individual variability of both markers, the use of longitudinal interpretations of the individual variations of both proteins during pregnancy should be preferred.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Glycated albumin (GA) may assess glycometabolic control over a short period of time respect to HbA
METHODS METHODS
Forty-five healthy pregnant Europid women have been enrolled for whom a GDM screening test was scheduled at 24-28 weeks, in 5 different Italian centers. Only those negative to the OGTT were included. The women had 4 successive visits at 6-10 weeks of gestation, at 16-18 weeks, at 24-28 weeks and at the end of pregnancy. ALT, AST, total bilirubin, C-reactive protein, cholinesterase, creatinine, GGT, glycated albumin, iron, total serum proteins, transferrin were measured in duplicate on aliquots of serum samples by a central laboratory.
RESULTS RESULTS
The RI (2.5-97.5 percentiles) for GA were 11.1-14.8 % (I visit), 10.9-15.6 % (II visit), 10.6-14.1 % (III visit) and 10.7-14.3 % (IV visit). The RI of other biomarkers confirmed previously published data. The RI for serum cholinesterase we present are novel, and were 5049-9906 U/L (Iv), 4212-8965 U/L (IIv), 3518-8470 U/L (IIIv) and 3945-8727 U/L (IVv).
CONCLUSIONS CONCLUSIONS
Trimester-specific RI are important for using GA and serum cholinesterase in pregnancy. However, considering the high inter-individual variability of both markers, the use of longitudinal interpretations of the individual variations of both proteins during pregnancy should be preferred.

Identifiants

pubmed: 36754193
pii: S0009-8981(23)00048-7
doi: 10.1016/j.cca.2023.117246
pii:
doi:

Substances chimiques

Blood Glucose 0
Glycated Serum Albumin 0
Glycated Hemoglobin 0
Glycation End Products, Advanced 0
Serum Albumin 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117246

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Renata Paleari (R)

Dip. di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, Milano, Italy; CIRME, Università degli Studi di Milano, Milano, Italy.

Matteo Vidali (M)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Patologia Clinica, Milano, Italy.

Ferruccio Ceriotti (F)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Patologia Clinica, Milano, Italy.

Basilio Pintaudi (B)

SSD Diabetologia, ASST Grande Ospedale metropolitano Niguarda, Milano, Italy.

Maria Luisa De Angelis (M)

SC Biochimica Clinica ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.

Ester Vitacolonna (E)

Dip. di Medicina e di Scienze dell'Invecchiamento, Università degli Studi "G. D'Annunzio", Chieti, Italy.

Ivana Cataldo (I)

SC Patologia Clinica Aziendale, ASL2 Lanciano Vasto Chieti, Chieti, Italy.

Elisabetta Torlone (E)

SC Endocrinologia e metabolismo, A.O. Univ. S. Maria della Misericordia, Perugia, Italy.

Elena Succurro (E)

Dip. di Scienze Mediche e Chirurgiche, Università degli Studi "Magna Graecia" di Catanzaro, Catanzaro, Italy.

Elvira Angotti (E)

UOC Biochimica Clinica, AOU Materdomini, Catanzaro, Italy.

Eugenio Alessi (E)

UOC Diabetologia ed Endocrinologia, G.O.M. "Bianchi, Melcrino, Morelli", Reggio Calabria, Italy.

Andrea Mosca (A)

Dip. di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, Milano, Italy. Electronic address: andrea.mosca@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH